News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
26,371 Results
Type
Article (4006)
Company Profile (4)
Press Release (22361)
Multimedia
Podcasts (35)
Webinars (4)
Section
Business (9857)
Career Advice (39)
Deals (1266)
Drug Delivery (27)
Drug Development (4495)
Employer Resources (12)
FDA (742)
Job Trends (1083)
News (15034)
Policy (1564)
Tag
2027 BioCapital Standard (2)
Academia (81)
Accelerated approval (3)
Adcomms (2)
Allergies (2)
Alliances (2273)
ALS (3)
Alzheimer's disease (42)
Antibody-drug conjugate (ADC) (121)
Approvals (759)
Artificial intelligence (33)
ASCO (66)
Autoimmune disease (15)
Automation (2)
Bankruptcy (9)
Best Places to Work (845)
BIO (1)
BIOSECURE Act (7)
Biosimilars (14)
BioSpace Insights (6)
Biotechnology (1)
Bladder cancer (27)
Brain cancer (11)
Breast cancer (87)
Cancer (630)
Cardiovascular disease (48)
Career advice (46)
Career pathing (2)
CAR-T (14)
CDC (14)
CDMO (21)
Cell therapy (28)
Cervical cancer (8)
Clinical research (3867)
Collaboration (108)
Commercialization (2)
Company closure (4)
Compensation (7)
Complete response letters (7)
COVID-19 (206)
CRISPR (3)
C-suite (128)
Cystic fibrosis (3)
Data (295)
Depression (4)
Dermatology (3)
Diabetes (11)
Diagnostics (98)
Digital health (2)
Diversity, equity & inclusion (3)
Drug discovery (19)
Drug pricing (51)
Drug shortages (1)
Duchenne muscular dystrophy (8)
Earnings (2346)
Editorial (10)
Employer branding (6)
Employer resources (12)
Events (2584)
Executive appointments (111)
Eye disease (1)
FDA (876)
Funding (75)
Gene editing (10)
Generative AI (3)
Gene therapy (17)
GLP-1 (84)
Government (339)
Grass and pollen (1)
Guidances (8)
Healthcare (486)
Hematology (7)
HIV (20)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (41)
Immuno-oncology (25)
Indications (17)
Infectious disease (238)
Inflammatory bowel disease (12)
Inflation Reduction Act (4)
Influenza (1)
Intellectual property (8)
Interviews (2)
IPO (378)
IRA (12)
Job creations (284)
Job search strategy (39)
JPM (9)
Kidney cancer (6)
Kidney disease (1)
Labor market (12)
Layoffs (70)
Leadership (4)
Legal (402)
Licensing (3)
Liver cancer (8)
Longevity (1)
Lung cancer (149)
Lymphoma (15)
Machine learning (2)
Management (4)
Manufacturing (62)
MASH (8)
Medical device (83)
Medtech (84)
Mergers & acquisitions (935)
Metabolic disorders (58)
mRNA (47)
Multiple sclerosis (14)
Neurodegenerative disease (20)
Neuropsychiatric disorders (10)
Neuroscience (93)
NextGen: Class of 2026 (200)
Non-profit (92)
Now hiring (4)
Obesity (38)
Opinion (38)
Ovarian cancer (28)
Pain (6)
Pancreatic cancer (11)
Parkinson's disease (6)
Patents (27)
Patient recruitment (15)
Patient selection (1)
People (4054)
Peptides (1)
Pharmaceutical (2)
Pharmacy benefit managers (3)
Phase 1 (1102)
Phase 2 (1720)
Phase 3 (1627)
Pipeline (393)
Policy (65)
Postmarket research (201)
Preclinical (280)
Press Release (2)
Prostate cancer (7)
Psychedelics (10)
Radiopharmaceuticals (20)
Rare diseases (40)
Real estate (213)
Recruiting (4)
Regulatory (1148)
Reports (7)
Research institute (74)
Resumes & cover letters (1)
RNA editing (2)
RSV (18)
Schizophrenia (4)
Series A (18)
Series B (11)
Sickle cell disease (3)
Special edition (8)
Spinal muscular atrophy (4)
Sponsored (2)
Startups (218)
Stomach cancer (9)
Supply chain (10)
Tariffs (23)
The Weekly (33)
Vaccines (173)
Venture capital (19)
Weight loss (32)
Women's health (5)
Worklife (2)
Date
Last 7 days (26)
Last 30 days (88)
Last 365 days (1034)
2026 (754)
2025 (1024)
2024 (1236)
2023 (1319)
2022 (2974)
2021 (2787)
2020 (2290)
2019 (1546)
2018 (1196)
2017 (1348)
2016 (1159)
2015 (1326)
2014 (867)
2013 (725)
2012 (785)
2011 (880)
2010 (816)
Location
Africa (65)
Alabama (4)
Alaska (1)
Arizona (3)
Asia (1642)
Australia (407)
California (305)
Canada (106)
China (142)
Colorado (6)
Connecticut (8)
Delaware (16)
Europe (4438)
Florida (75)
Georgia (3)
Illinois (14)
India (3)
Indiana (3)
Japan (76)
Kansas (1)
Kentucky (1)
Maryland (71)
Massachusetts (324)
Michigan (1)
Minnesota (6)
Mississippi (1)
Missouri (4)
Montana (1)
Nevada (2)
New Hampshire (5)
New Jersey (356)
New York (99)
North Carolina (29)
Northern California (167)
Ohio (3)
Oregon (1)
Pennsylvania (35)
Rhode Island (4)
South America (61)
South Carolina (1)
Southern California (107)
Tennessee (2)
Texas (33)
United States (1389)
Utah (9)
Virginia (8)
Washington D.C. (5)
Washington State (35)
West Virginia (1)
Wisconsin (3)
26,371 Results for "merck kgaa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
The company is “especially excited” about an immune cell therapy manufacturing technology included in the deal, a Merck KGaA executive said.
June 26, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
September 23, 2026
·
6 min read
Eye disease
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
September 24, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Evinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical Development
July 29, 2026
·
3 min read
Drug Development
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’s Humira and UCB’s Bimzelx.
October 1, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need to be replicated in non-Chinese patients.
September 3, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
June 25, 2026
·
18 min read
Press Releases
Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies
June 24, 2026
·
4 min read
Business
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs
BMO Capital Markets is more impressed by Merck’s plans to replace lost Keytruda revenue than on Bristol Myers Squibb’s efforts to fill the expected void that will come from loss of exclusivity for both Opdivo and Eliquis.
October 2, 2026
·
4 min read
·
Gabrielle Masson
Lung cancer
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
Merck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Capital Markets.
September 28, 2026
·
2 min read
·
Tristan Manalac
1 of 2,638
Next
